December 28, 2015 – Could hypnosis help to reduce the psychological trauma associated with "awake craniotomy" for brain cancers? A new "hypnosedation" technique offers a new alternative for patients undergoing awake surgery for gliomas, suggests a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer.
Initial evaluation shows a high rate of successful hypnosis in patients undergoing "awake craniotomy" for brain cancer (glioma), report Dr. Ilyess Zemmoura of Centre Hospitalier Universitaire de Tours, France, and colleagues. They believe that hypnosedation might be especially valuable in patients with more advanced brain cancers.
Hypnosis Provides Sedation and Relaxation during 'Awake' Brain Surgery
Dr. Zemmoura and colleagues evaluated their hypnosis technique in 37 patients undergoing awake craniotomy, mainly for low-grade gliomas, between 2011 and 2015. In awake craniotomy, the patient is sedated but conscious so as to be able to communicate during the operation. This helps the surgeon navigate safely to the tumor without damaging the "eloquent cortex"–critical areas of the brain involved in language or movement.
Preparation for hypnosis began a few weeks before surgery. The anesthesiologist/hypnotist met with the patient to carry out a short hypnosis session and teach the patient how to create a "safe place"–an imaginary place where they can feel safe and effective.
In the operating room, patients were placed in a hypnotic trance; for example, they were instructed to "let go" and to "separate the mind and body." The hypnotic experience was progressively enhanced during the first steps of surgery, including specific instructions and imagery for each potentially unpleasant or painful step of the surgery. (The online version of the article includes a detailed description and video of the hypnosedation procedure.)
The 37 patients underwent a total of 43 surgeries with hypnosedation (including repeat surgeries in patients with recurrent gliomas). Hypnosis failed in six patients, who underwent standard "asleep-awake-asleep" anesthesia. Another two patients decided not to undergo hypnosis.
When successful, hypnosis was a reliable and reproducible method for awake surgery, with questionnaire assessments showing little or no negative psychological impact. Rather than any measure of individual "hypnotizability," the success of hypnosis seemed to be most strongly related to the patients' motivation and determination.
Hypnosedation seemed to reduce the impact of unpleasant events during surgery. Some patients reported high stress levels, but this did not appear to affect their subjective experience of hypnosis. The one patient who showed signs of posttraumatic stress disorder after surgery had a particularly good experience with hypnosis.
For patients, the most unpleasant parts of surgery were steps involving noise and vibration. Pain seemed to decrease as the level of hypnosis deepened. Only two patients said they would not choose to undergo hypnosedation if they had to undergo a second awake craniotomy.
An important advantage of hypnosedation is that it allows the patient to remain awake throughout surgery. This avoids the need to awaken the patient in the middle of standard "asleep-awake-asleep" anesthesia–which can be especially challenging in patients with high-grade gliomas. The authors note that their experience included successful hypnosedation in two patients with high-grade gliomas.
While the initial evaluation is encouraging, Dr. Zemmoura and colleagues note that it provides no evidence that hypnosedation is superior to standard anesthesia. They also emphasize the considerable investment of time and commitment needed to prepare for and carry out their hypnosis technique: "It requires intense involvement and long training of the whole team, including the patient."
Article: "Hypnosis for Awake Surgery of Low-grade Gliomas: Description of the Method and Psychological Assessment" (doi: 10.1227/NEU.0000000000000993)
Neurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit http://www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on http://www.youtube.com/user/WoltersKluwerComms">YouTube